Notes from our applied science and market teams—methodology explainers, regulatory snapshots, and practical workflows for evidence-heavy decisions.
Featured this month
A short editorial on why exportable, attributable snapshots beat giant slide decks—and how we think about defaults for IC-ready PDFs versus live dashboards.
Trial design
March 12, 2026
7 min read
When interim looks and sample-size re-estimation are in play, what matters for investors is pre-specification, alpha spending, and whether the trial can still answer its primary question.
Regulatory
February 28, 2026
5 min read
A data-forward look at approval cadence, advisory committee clustering, and how label revisions tracked against Khora credibility scores six months prior.
Workflow
February 4, 2026
6 min read
How BD teams collapse arm-level efficacy, safety deltas, and competitor windows into a single decision-ready brief—and when to escalate to a full diligence thread.
Oncology
January 19, 2026
8 min read
Why cross-trial comparison still fails gracefully, and how hierarchical modeling plus contextual flags reduces false confidence in immuno-oncology baskets.
Biweekly email: three charts, one regulatory note, and a single workflow idea. No sponsored content; unsubscribe any time.
